Novaliq Announces First Patient Enrolled in Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Dry Eye Disease

Novaliq announces first PATIENT Enrolled in ITS SEECASE phase 2 trial OF NOV03  FOR THE TREATMENT of dry eye disease Heidelberg, Germany – January 8, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that it has begun randomization of patients in its SEECASE Phase 2 clinical trial for the treatment of dry eye disease (DED).

Details

Novaliq’s NovaTears®+Omega-3 Approved in Europe for the Enhanced Treatment of Evaporative Dry Eye Disease

Heidelberg, Germany – December 6, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the European registration of NovaTears®+Omega-3 for the enhanced treatment of the signs and symptoms of evaporative dry eye disease (DED).

Details

Novaliq announces first patient randomized in its ESSENCE phase 2b/3 trial of CyclASol® for the treatment of the signs and symptoms of dry eye disease

Heidelberg, Germany – November 9, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that it has begun randomization of patients in its ESSENCE Phase 2b/3 clinical trial that will evaluate CyclASol® for the treatment of the signs…

Details

Novaliq’s NovaTears® treatment for evaporative dry eye disease launches in New Zealand and receives registrational approval in Australia

Heidelberg, Germany – October 30, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the launch of NovaTears® in New Zealand and registrational approval in Australia. According to McCarty, the prevalence of dry eye disease (DED) is approximately…

Details